Figure 1 | Scientific Reports

Figure 1

From: Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastoma

Figure 1

The association of cyclophosphamide therapeutic outcome with patients’ CYP2B6 (A) and CYP2C19 genotype-based phenotypes (B). Patients were considered to be responders with complete remission and partial remission, whereas non-responders with stable disease and progressive disease/exit. CYP2B6 and CYP2C19 phenotypes were estimated on the basis of CYP2B6 or CYP2C19 genotypes according to the CPIC and PharmVar recommendations.

Back to article page